文献速递心脑血管急症复苏、休克与脓毒症

ST段抬高型心肌梗死直接PCI患者院前与院内普通肝素比较:系统评价与荟萃分析

Prehospital versus in-hospital unfractionated heparin in ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis.
PubMed 文献 · Eur J Emerg Med · 2026-09-02
一句话结论STEMI直接PCI患者院前给予普通肝素可提高术前TIMI 2-3血流且不增加大出血,但30天死亡率无显著下降。

该系统评价与荟萃分析纳入7项研究(2项RCT、5项观察性研究),共10 954例拟行直接PCI的STEMI患者,比较院前与院内普通肝素给药。院前普通肝素与术前TIMI 2-3血流率显著升高相关(OR 1.49,95%CI 1.28-1.74),30天或住院死亡复合终点显著降低(OR 0.68,95%CI 0.49-0.95),但30天全因死亡无显著降低(OR 0.70,95%CI 0.44-1.13),大出血无显著增加(OR 0.77,95%CI 0.57-1.05)。结论需大规模RCT验证临床终点。

要点

  • STEMI直接PCI患者院前普通肝素较院内给药提高术前TIMI 2-3血流率(OR 1.49,95%CI 1.28-1.74,P<0.001)。
  • 院前普通肝素未显著降低30天全因死亡(OR 0.70,95%CI 0.44-1.13,P=0.141,I2=60.9%)。
  • 30天或住院死亡复合终点在全部7项研究中显著降低(OR 0.68,95%CI 0.49-0.95,P=0.023)。
  • 院前普通肝素未显著增加大出血风险(OR 0.77,95%CI 0.57-1.05,P=0.099,I2=0%)。
  • 结论需大规模、以临床终点为效力的RCT确立院前普通肝素在当代STEMI救治中的地位。

适用人群与场景

  • 拟行直接PCI的STEMI患者,来自7项研究(2项RCT、5项观察性研究),共10 954例,78.1%为男性。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 系统评价与荟萃分析,纳入7项研究(2项RCT、5项观察性研究),共10 954例拟行直接PCI的STEMI患者,78.1%男性。
  • 干预为院前普通肝素给药,对照为PCI医院内普通肝素给药。
  • 主要终点:院前普通肝素组术前TIMI 2-3血流率显著高于对照(OR 1.49,95%CI 1.28-1.74,P<0.001)。
  • 30天全因死亡无显著降低(OR 0.70,95%CI 0.44-1.13,P=0.141,I2=60.9%)。
  • 30天或住院死亡复合终点在全部7项研究中显著降低(OR 0.68,95%CI 0.49-0.95,P=0.023)。
  • 大出血无显著增加(OR 0.77,95%CI 0.57-1.05,P=0.099,I2=0%)。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入2项RCT和5项观察性研究。
  • 局限:纳入研究以观察性研究为主(5/7),30天全因死亡分析异质性I2=60.9%,原文结论指出需大规模RCT以临床终点为效力进一步验证。

对床旁实践的改变

  • 对拟行直接PCI的STEMI患者,院前给予普通肝素可能提高术前梗死相关动脉通畅率(TIMI 2-3血流),且未观察到大出血风险显著增加。
  • 院前普通肝素对30天全因死亡的无显著获益提示不能仅凭复合终点或通畅率替代硬终点决策,需待大规模RCT证实。
  • 原文未提及具体给药剂量、途径、频次及适用/不适用人群,床旁实施时不能从本文推断具体方案。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND AND IMPORTANCE: In patients with ST-segment elevation myocardial infarction (STEMI), myocardial loss continues until coronary reperfusion is achieved.

OBJECTIVE: To evaluate whether prehospital administration of unfractionated heparin (UFH) improves preprocedural infarct-related artery patency and clinical outcomes in patients undergoing primary percutaneous coronary intervention (PCI).

DESIGN: Systematic review and meta-analysis. Electronic databases (PubMed, EMBASE, CENTRAL, and Web of Science) and clinical trial registries were systematically searched through March 2026.

SETTINGS AND PARTICIPANTS: Patients with STEMI scheduled for primary PCI across seven included studies (two randomized controlled trials and five observational studies), totaling 10 954 participants, with 78.1% male patients.

INTERVENTION OR EXPOSURE: Prehospital UFH administration compared with PCI-capable hospital UFH administration.

OUTCOME MEASURES AND ANALYSIS: Prespecified endpoints included pre- and postprocedural thrombolysis in myocardial infarction (TIMI) flow grade, 30-day mortality, a composite endpoint of 30-day or in-hospital mortality, and major bleeding events.

MAIN RESULTS: Prehospital UFH was associated with a significantly higher rate of preprocedural TIMI 2-3 flow compared with control [odds ratio (OR): 1.49, 95% confidence interval (CI): 1.28-1.74; P < 0.001). Prehospital UFH was not associated with a significant reduction in 30-day all-cause mortality (OR: 0.70, 95% CI: 0.44-1.13; P = 0.141; I2 = 60.9%), although a significant reduction was observed for the composite endpoint of 30-day or in-hospital mortality across all seven studies (OR: 0.68, 95% CI: 0.49-0.95; P = 0.023). Prehospital UFH was not associated with a significantly increased risk of major bleeding (OR: 0.77, 95% CI: 0.57-1.05; P = 0.099; I2 = 0%).

CONCLUSION: In patients with STEMI undergoing primary PCI, prehospital UFH was associated with improved preprocedural coronary patency without an apparent increase in major bleeding. However, no statistically significant reduction was observed in 30-day mortality. Large-scale randomized controlled trials adequately powered for clinical endpoints are needed to establish the role of prehospital UFH in contemporary STEMI care.

来源:Eur J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Wu YJ, Lin HJ, Lin YH, et al. Prehospital versus in-hospital unfractionated heparin in ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis. Eur J Emerg Med. 2026. PMID: 42684123. doi:10.1097/MEJ.0000000000001371

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。